Immuron Limited Clinical Trial Update

Immuron Limited provided an update on its clinical trials for Travelan® and IMM-529. The company announced that the Investigational New Drug (IND) application for IMM-529, aimed at preventing or treating Clostridioides difficile infection, is under active review by the FDA. Immuron has submitted additional information and updated the clinical trial protocol in response to FDA requests. Additionally, the topline results for the Travelan® Phase 2 clinical trial, conducted by the Uniformed Services University, are delayed until the end of November 2025 due to a U.S. government shutdown. The results of this study will influence Immuron's dosing strategy for its upcoming End-of-Phase 2 meeting with the FDA.